Cetera Advisor Networks LLC Argenx Se Transaction History

Cetera Advisor Networks LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$356.95 - $413.29 $149,919 - $173,581	-420 Reduced 37.84%	690 $271,000
Q4 2023 Feb 13, 2024	SELL	$338.91 - $506.01 $51,853 - $77,419	-153 Reduced 12.11%	1,110 $422,000
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $20,683 - $30,712	56 Added 4.64%	1,263 $620,000
Q2 2023 Aug 09, 2023	BUY	$360.14 - $422.58 $104,080 - $122,125	289 Added 31.48%	1,207 $470,000
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $22,059 - $26,640	-66 Reduced 6.71%	918 $342,000
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $336,695 - $395,873	984 New	984 $372,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.